Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update
March 05, 2020 07:30 ET
|
Arbutus Biopharma Corporation
Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic...
Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results
February 27, 2020 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its...
Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer
February 10, 2020 08:00 ET
|
Arbutus Biopharma Corporation
Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its...
Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 06, 2019 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019...
Arbutus to Report Third Quarter 2019 Financial Results
October 30, 2019 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its...
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B
October 03, 2019 16:05 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue...
Arbutus to Participate in Upcoming Investor Conferences
September 26, 2019 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the...
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
August 20, 2019 16:05 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that...
Arbutus to Participate at Wedbush PacGrow Healthcare Conference
August 06, 2019 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 05, 2019 07:30 ET
|
Arbutus Biopharma Corporation
- Appointed William Collier, with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent...